Skip to main content

Recombinant Mouse Integrin alpha L beta 2 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 7825-AB

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
7825-AB-050

Key Product Details

Source

CHO

Structure / Form

Noncovalently-linked heterodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived mouse Integrin alpha L beta 2 protein
Mouse Integrin alphaL
(Tyr24-Glu1084)
Accession # P24063
His-Pro GGGSGGGS Acidic Tail 6-His tag
Mouse Integrin beta2
(Gln24-Asn702)
Accession # P11835
His-Pro GGGSGGGS Basic Tail
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Tyr24 (Integrin  alphaL) & Gln24 predicted: No results obtained, sequencing might be blocked (Integrin beta2)

Predicted Molecular Mass

126 kDa (Integrin alphaL) & 83 kDa (Integrin beta2)

SDS-PAGE

95-105 kDa & 155-175 kDa, reducing conditions

Activity

Measured by the ability of the immobilized protein to support the adhesion of CHO Chinese hamster ovary cells transfected with ICAM-1.
The ED50 for this effect is 0.3-1.2 μg/mL.

Formulation, Preparation and Storage

7825-AB
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 400 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Integrin alpha L beta 2

Integrin alphaL beta2, also called LFA-1, is one of three beta2 integrin adhesion proteins. The non‑covalent heterodimer of 180 kDa alphaL/CD11a and 95 kDa beta2/CD18 integrin subunits is expressed on virtually all leukocytes (1‑3). The ligand binding site of LFA-1 is in the N-terminal head region, formed by an interaction of the vWFA
(I, I‑like) domains from each subunit, and the alphaL beta-propeller structure (3‑5). The alphaL subunit contains domains termed thigh, calf-1 and calf-2, while the beta2 subunit contains a PSI (plexin-semaphorin-integrin) region and four cysteine-rich I-EGF folds (3). Each subunit has a transmembrane sequence and a short cytoplasmic tail connected to the cytoskeleton. Upon activation by “inside‑out” signaling, clustering, or Mg2+ or Mn2+ binding to metal ion-dependent adhesion sites (MIDAS) within the vWFA domains, the molecule unfolds from its inactive, “closed” conformation to expose ligand binding sites (3‑7). Active alphaL beta2 binds ICAM-1/CD54, ICAM-2, ICAM-3 and JAM-A (1, 8‑10). The adhesion stabilizes interactions between T cells and antigen-presenting cells, decreases the T cell activation threshold, and facilitates transendothelial migration of neutrophils and other leukocytes to sites of inflammation (10‑13). Blockade of LFA-1 may inhibit graft vs. host disease and transplant rejection (14). A constitutively active construct severely impairs immune responses, demonstrating that both activation and de-activation are important (12). Mutations of beta2, especially in the vWFA domain, cause leukocyte adhesion deficiency (LAD-1) and susceptibility to bacterial infections (15). The 1065 amino acid (aa) mouse alphaL/CD11b ECD shares 87% aa sequence identity with rat, and 70‑74% with human, equine, bovine, porcine, and canine  alphaL ECD. Potential mouse alphaL isoforms of 626 and 601 aa have alternate N- or C-termini, respectively. The 679 aa mouse beta2/CD18 ECD shares 91% aa sequence identity with rat, and 80-82% with human, bovine, canine, and porcine beta2 ECD.

References

  1. Larson, R.S. et al. (1989) J. Cell Biol. 108:703.
  2. Kishimoto, T.K. et al. (1987) Cell 48:681.
  3. Hogg, N. et al. (2011) Nat. Rev. Immunol. 11:416.
  4. Beglova, N. et al. (2002) Nat. Struct. Biol. 9:282.
  5. Shimaoka, M. et al. (2003) Immunity 19:391.
  6. Lu, C. et al. (2004) J. Immunol. 173:3972.
  7. Cairo, C.W. et al. (2006) Immunity 25:297.
  8. Nortamo, P. et al. (1991) J. Immunol. 146:2530.
  9. de Fougerolles, A.R. and T.A. Springer (1992) J. Exp. Med. 175:185.
  10. Ostermann, G. et al. (2002) Nat. Immunol. 3:151.
  11. Heit, B. et al. (2005) J. Cell Sci. 118:5205.
  12. Semmrich, M. et al. (2005) J. Exp. Med. 201:1987.
  13. Dixit, N. et al. (2011) J. Immunol. 187:472.
  14. Reisman, N.M. et al. (2011) Blood 118:5851.
  15. Kishimoto, T.K. et al. (1987) Cell 50:193.

Entrez Gene IDs

3683 (Human)

Gene Symbol

ITGAL

Additional Integrin alpha L beta 2 Products

Product Documents for Recombinant Mouse Integrin alpha L beta 2 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse Integrin alpha L beta 2 Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...